Une candidature complète en une minute
Un CV et une lettre de motivation personnalisés, prêts à envoyer.
University Hospital Schleswig-Holstein seeks a doctoral researcher to join the LUCID-AML project focused on learning-based clustering of transcriptomics to define AML subtypes across ages. The initial appointment is for three years with the possibility of extension, offering a PhD opportunity and access to a large AML transcriptomics resource.
You will collaborate with computational and clinical scientists, gain training in ML and reproducible research, and contribute to open-source tooling and
The position is part of the newly established research project “LUCID-AML – Learning-based Unsupervised Clustering of transcriptomIcs to Detect developmental, functional and prognostic subtypes in AML across age”, funded by the Deutsche José Carreras Leukämie-Stiftung. It is closely linked to our DFG-funded Clinical Research Unit “CATCH-ALL: Towards a Cure for Adults and Children with Acute Lymphoblastic Leukemia”, where clinical and basic researchers work together to define mechanisms of leukemogenesis and treatment resistance across age groups.
Acute myeloid leukemia (AML) affects people of all ages, but its incidence increases steeply in older adults, while survival decreases sharply with age. AML can be classified into transcriptomic groups that reflect cytogenetic lesions, reveal developmental origins and link leukemias to normal hematopoietic states. However, consistent subtype definitions and robustly validated tools for applying them across cohorts are lacking.
The project builds on ALLCatchR and our work on machine-learning frameworks for disease classification and the identification of novel molecular subtypes in acute lymphoblastic leukemia. LUCID-AML will integrate more than 8,000 bulk AML gene-expression profiles from multiple cohorts with single-cell data, molecular genetics, diagnostic classifications, drug-response data and clinical outcomes. The project aims to establish reproducible, gene-expression-based AML subtypes while accounting for age and treatment. Further aims are to define their developmental origins and make the resulting models available as transparent, open-source tools for research and clinical diagnostics. For further reading: Beder et al., HemaSphere, 2023; Bastian et al., Blood, 2024; Beder et al., bioRxiv / HemaSphere, 2026.
Join our team as soon as possible. The initial appointment is for three years, with the possibility of extension.